U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129499) titled 'Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas' on Aug. 07.
Brief Summary: This multicenter, randomized, double-blind, placebo-controlled trial will enroll 450 patients with completely resected high-risk colorectal adenoma (HR-CRA), randomly assigned (1:1) to 6 months of Shenbai Granules (SBG) or placebo, followed for 3 years post-polypectomy. Primary endpoint: 3-year cumulative incidence of metachronous HR-CRA. Secondary endpoints: incidence, number, size, distribution, histology of low-risk adenomas and serrated lesions, and colorectal cancer occurrence.
Study Start Date: Aug. 15
Study ...